Profile: Discovery Laboratories Inc (DSCO.O)

DSCO.O on Consolidated Issue listed on NASDAQ Capital Market

1.61USD
27 Feb 2015
Change (% chg)

$-0.02 (-1.23%)
Prev Close
$1.63
Open
$1.64
Day's High
$1.64
Day's Low
$1.58
Volume
265,403
Avg. Vol
367,232
52-wk High
$2.77
52-wk Low
$0.99

Search Stocks

Discovery Laboratories, Inc., incorporated on May 18, 1993, is a specialty biotechnology company. The Company is focused on creating life-saving products for critical-care patients with respiratory distress syndrome (RDS) and improving the standard of care in pulmonary medicine. The Company’s drug technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival.

The Company’s KL4 surfactant drug product, SURFAXIN (lucinactant) Intratracheal Suspension is for the prevention of RDS in premature infants for RDS. SURFAXIN is the Company’s KL4 surfactant in liquid form, and is the synthetic, peptide-containing surfactant approved by the FDA and the only alternative to animal-derived surfactants.

AEROSURF is the Company’s investigational combination drug or device product that combines KL4 surfactant with capillary aerosol generator (CAG). AEROSURF enable administration of aerosolized KL4 surfactant to premature infants supported with nCPAP, without invasive intubation and mechanical ventilation. The Company is conducting a Phase IIA clinical trial for AEROSURF for the treatment of RDS in premature infants. The Company is also preparing for the Phase IIB clinical trial and has identified four new clinical sites.

The Company is developing a lyophilized (freeze-dried) dosage form of its KL4 surfactant that is stored as a powder and reconstituted to liquid form prior to use with the objective of improving ease of use for healthcare practitioners, as well as prolong shelf life and eliminate the need for cold-chain storage. The Company is developing this dosage form for use in its AEROSURF development program.

The Company competes with Chiesi Farmaceutici S.p.A., Cornerstone Therapeutics Inc., Abbott Nutritionals, Inc., ONY, Inc., Pari and Aerogen.

Company Address

Discovery Laboratories Inc

Suite 100, 2600 Kelly Road
WARRINGTON   PA   18976-3622
P: +1215.4889300
F: +1215.4889301

Company Web Links

Search Stocks